

I hope this email finds you well.

Further to the call of 17 September and as requested by the EMA representatives, please find attached a Vaccines Europe paper on "Global management of CMC Post- Approval Changes for COVID-19" where additional information/examples are given.

Could you please be so kind and share this paper with [REDACTED] and [REDACTED]
[REDACTED]

Best regards,

[REDACTED]

[REDACTED]

Vaccines Europe
Rue du Trône 108, B-1050 Brussels

[REDACTED]

Tel: [+32\(2\)626.25.55](tel:+3226262555) (Switchboard)

[REDACTED]

[\[REDACTED\]@vaccineseuropa.eu](mailto:[REDACTED]@vaccineseuropa.eu)

www.vaccineseuropa.eu

Transparency Register ID: 53073567234-18

